Advertisement

Reactions Weekly

, Volume 1710, Issue 1, pp 10–10 | Cite as

Secukinumab, ixekizumab: ulcerative colitis, Crohn's disease

Clinical study
  • 23 Downloads

Reference

  1. Orrell KA, et al. Inflammatory bowel disease events after exposure to the IL-17 inhibitors, secukinumab and ixekizumab: A post-marketing analysis from the RADAR (Research on Adverse Drug events And Reports) Program. Journal of the American Academy of Dermatology : 16 Jun 2018. Available from: URL: http://doi.org/10.1016/j.jaad.2018.06.024

Copyright information

© Springer Nature Switzerland AG 2018

Personalised recommendations